AP-472 is under clinical development by Appello Pharmaceuticals and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AP-472’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AP-472 overview
AP-472 is under development for the treatment of Parkinson's disease. The drug candidate is positive allosteric modulators (PAMs) of the metabotropic glutamate receptor subtype 4.
Appello Pharmaceuticals overview
Appello Pharmaceuticals is a neurology therapeutics company. It primarily focuses on the identification and development of innovative early-stage drugs. The company mainly focus on improving the lives of patients living with disorders of the central nervous system (CNS). Appello’s product in development is a novel Parkinson’s therapeutic, AP-472, that is currently in Phase I clinical trials. The company also develops highly selective drugs that modulate specific metabotropic glutamate receptors (mGlus) to treat various CNS disorders. These drugs are designed for patients suffering from neurological conditions, particularly those related to glutamate activity in the CNS. Appello Pharmaceuticals is headquartered in Nashville, Tennessee, the US.
For a complete picture of AP-472’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
